Search results: (10000)
News Webinar SGLT2i in ESC HF Guidelines vs. Real Practice
Dear Doctor,
Boehringer Ingelheim, in collaboration with the 2nd Department of Internal Medicine - Department of Cardiology and Angiology,
General University Hospital and 1st Faculty of Medicine, Charles University, cordially invites you to an online discussion to be held on Tuesday, November 23, 2021, from 5 : 00 PM to 6 : 30 PM.
More information can be found in the attached invitation below.
News Mechanisms of Cardioprotective Effects of SGLT2 Inhibitors
Inhibitors of sodium-glucose cotransporter 2 (SGLT2i, gliflozins) are a relatively new group of medications used in the treatment of type 2 diabetes mellitus (T2DM). Their clinical use is supported by the results of extensive clinical studies, which have particularly demonstrated their cardioprotective and renoprotective effects.
News Efficacy of Brigatinib in Patients with Metastatic NSCLC − Real-World Clinical Data
The journal Lung Cancer published the results of a retrospective analysis of the efficacy of brigatinib in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who participated in a European early access treatment program.
News Monocyte Distribution Width Indicates Sepsis Regardless of Sepsis Etiology
Patients in intensive care units represent a high-risk population for the development of sepsis, which is one of the primary causes of mortality in these settings. The aim of the recently published study was to evaluate the diagnostic accuracy and prognostic properties of the monocyte distribution width parameter in septic patients.
News What does the analysis of the CHESS PAEDs study say about the relationship between physical activity and the frequency of bleeding events in children with hemophilia A?
Currently, there is limited published data addressing the relationship between physical activity and the occurrence of bleeding events in children with hemophilia A. To gain insights into this topic in real-world practice, data from the CHESS PAEDs study were analyzed. The results were presented in the poster section of the virtual congress of the International Society on Thrombosis and Haemostasis (ISTH).
News Final Analysis of the STASEY Study: How Did Emicizumab Perform in Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?
The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a range of interesting topics. In its poster section, data from the multicenter single-arm open-label phase III clinical trial STASEY, which evaluated the safety and tolerance of emicizumab prophylaxis in patients with hemophilia A and an inhibitor of coagulation factor VIII (FVIII), were presented. Víctor Jiménez-Yuste from La Paz University Hospital in Madrid presented the study results on behalf of the international team of authors.
News Gene Therapy for Hemophilia A: What is the Expression of Factor VIII Using the Adeno-Associated Viral Vector SPK-8011?
The goal of gene therapy for hemophilia A is to safely transfer stable and durable expression of coagulation factor VIII (FVIII), which predictably improves the bleeding phenotype at the lowest possible vector dose. Updated data from a study examining the use of the adeno-associated viral vector (AAV) SPK-8011 were presented during the virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021.
News Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis
Data from randomized clinical trials have shown that romiplostim is an effective medication for many patients not only with acute or persistent immune thrombocytopenia (ITP) but also for much more complicated patients with chronic ITP. In April 2021, data on the efficacy and safety of romiplostim from European clinical practice were published.
News How TPO-RA Drugs Fared in Meta-Analyses of Safety and Efficacy in ITP Patients
Meta-analyses regarding the use of thrombopoietin receptor agonists (TPO-RA) evaluated their efficacy and safety in the treatment of primary immune thrombocytopenia over long-term follow-ups. What findings did they uncover?
News Expanded Hemodialysis and Its Impact on Reducing Hospitalization Rates and Medication Usage
The number of patients with end-stage kidney disease is increasing. New approaches and technological advancements in recent decades have contributed to improving hemodialysis treatment. Does the use of so-called expanded hemodialysis lead to better outcomes?
News How Does Emicizumab Work in Obese Adults with Hemophilia A?
What is the annual bleeding rate and minimum concentration of emicizumab in obese adults with hemophilia A compared to non-obese individuals? Answers were sought by the authors of a pooled post hoc analysis of the HAVEN 1, 3, and 4 studies, the results of which were presented in the poster section of the 2021 ISTH virtual congress. Based on modeling, body weight appears to be an important predictor of emicizumab pharmacokinetics.
News Mental Health During the Pandemic − and How to Alleviate Its Impacts
At the symposium during the XV Spring Interactive Conference of the General Medical Society of ČLS JEP, which was eventually held in September 2021 in Prague, Prof. MUDr. Cyril Höschl, DrSc., FRCPsych, presented his lecture on the impacts of the COVID-19 pandemic on mental health. At the end of his speech, he also addressed the practical issue of selecting a suitable antidepressant.
News Stabilization of Liver Metastases of CRC with Trifluridine/Tipiracil in 3rd Line Therapy – Case Study
We present a case study of a man born in 1944 who underwent resection of the rectosigmoid for multiple adenocarcinomas in February 2016. Subsequently discovered liver metastases were managed with several lines of palliative therapy in combination with repeated surgical resections. Trifluridine/tipiracil administered in the 3rd line represents a well-tolerated oral treatment for this patient, on which he achieved disease stabilization.
News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency
Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.
News Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin
Authors of the British study SUGAR-DM-HF published in February 2021 examined whether empagliflozin reduces left ventricle (LV) volume in patients with type 2 diabetes mellitus (DM), prediabetes, and heart failure with reduced ejection fraction (EF). This favorable reverse remodeling of the LV could be a mechanism through which empagliflozin achieves reduced hospitalization rates for heart failure and overall mortality in these patients.